ArticleBiochemistry2025
α-Helical Structure of Antimicrobial Peptides Enhances Their Activity through Molecular Surface Signatures.
Article in Biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Cooperative membrane association as a mechanistic origin of synergistic antimicrobial peptide activity.RSC chemical biology · 2026Review
- Exploring the antibacterial potential of a designed peptide against Gardnerella vaginalis.Molecular biology reports · 2026Article
- Peptide ligands to explore interactions with intrinsically disordered multidomain proteins: the case of SARS-CoV-2 nucleocapsid protein.Scientific reports · 2026Article
- Cyclodextrin and KR12-Lipopeptide Interactions: A Thermodynamic View of Binding Mechanisms and Impact on the Structure of α-Helical Peptides.The journal of physical chemistry. B · 2026Article
- Rational Design and Optimization of MCh-AMP1: A Stable α-Helical Antifungal Peptide with Enhanced Activity AgainstDrug design, development and therapy · 2026Article
- Experimental screening and structure-informed engineering of peptide-fused bacteriophage lysins with enhanced activity against Gram-negative bacteria.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increase in antibacterial resistance is one of the greatest challenges in modern medicine, driving an urgent need to develop new drugs to combat resistant pathogens. Peptides represent a promising class of molecules that can be efficiently designed to exhibit high antimicrobial efficacy. Recently, we have highlighted how prestructuring by a triazolyl-bridge significantly enhances the activity of an antimicrobial peptide. To learn more from these findings, the aim of this study is to relate the NMR-based structure of a triazolyl-bridged peptide to its antimicrobial activity against Gram-positive and Gram-negative bacteria in comparison to its linear analogues. As we show, the triazole modification indeed induces a well-defined α-helical structure, resulting in an improved positive electrostatic surface potential on one side of the peptide and clustering of hydrophilic and hydrophobic residues on opposite surface areas of the molecule. Systematic alanine substitution further suggested that the side chains of arginine 3 and 7 and of asparagine 11 have a stronger productive impact on antimicrobial activity than those of lysine 4, 8, and 12. As shown by micelle-bound peptide structures determined by NMR, we identify arginine 3 and asparagine 11 as presumable membrane-interacting residues. Collectively, our NMR-based analysis provides evidence that an α-helical structure enhances antimicrobial activity by creating positively charged and hydrophilic, and hydrophobic areas as molecular surface signatures, potentially promoting the interaction of the peptide with the cellular target membrane.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.